{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:15:37Z","timestamp":1793643337827,"version":"4.5.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s00277-023-05246-x","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T17:01:57Z","timestamp":1683133317000},"page":"1301-1306","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Ofatumumab regimens in chronic lymphocytic leukemia: a meta-analysis"],"prefix":"10.1007","volume":"102","author":[{"given":"Muhammad Hossein","family":"Ashoub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirreza","family":"Naseri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parisa","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5722-8300","authenticated-orcid":false,"given":"Masoud","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"issue":"2","key":"5246_CR1","doi-asserted-by":"publisher","first-page":"a035220","DOI":"10.1101\/cshperspect.a035220","volume":"11","author":"N Chiorazzi","year":"2021","unstructured":"Chiorazzi N, Chen SS, Rai KR (2021) Chronic Lymphocytic Leukemia. Cold Spring Harb Perspect Med 11(2):a035220","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"5246_CR2","doi-asserted-by":"publisher","first-page":"894","DOI":"10.3390\/cancers12040894","volume":"12","author":"JA Cohen","year":"2020","unstructured":"Cohen JA, Bomben R, Pozzo F, Tissino E, H\u00e4rzschel A, Hartmann TN et al (2020) An updated perspective on current prognostic and predictive biomarkers in chronic lymphocytic leukemia in the context of chemoimmunotherapy and novel targeted therapy. Cancers 12(4):894","journal-title":"Cancers"},{"issue":"1","key":"5246_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12938-021-00973-6","volume":"21","author":"Y Yao","year":"2022","unstructured":"Yao Y, Lin X, Li F, Jin J, Wang H (2022) The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019. Biomed Eng Online 21(1):4","journal-title":"Biomed Eng Online"},{"issue":"5","key":"5246_CR4","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/j.1365-2141.2007.06856.x","volume":"139","author":"GM Dores","year":"2007","unstructured":"Dores GM, Anderson WF, Curtis RE, Landgren O, Ostroumova E, Bluhm EC et al (2007) Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol 139(5):809\u2013819","journal-title":"Br J Haematol"},{"issue":"3","key":"5246_CR5","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1080\/10428194.2019.1680840","volume":"61","author":"R Weide","year":"2020","unstructured":"Weide R, Feiten S, Chakupurakal G, Friesenhahn V, Kleboth K, K\u00f6ppler H et al (2020) Survival improvement of patients with chronic lymphocytic leukemia (CLL) in routine care 1995\u20132017. Leuk Lymphoma 61(3):557\u2013566","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"5246_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1365-2354.2011.01278.x","volume":"21","author":"J Evans","year":"2012","unstructured":"Evans J, Ziebland S, Pettitt AR (2012) Incurable, invisible and inconclusive: watchful waiting for chronic lymphocytic leukaemia and implications for doctor-patient communication. Eur J Cancer Care (Engl) 21(1):67\u201377","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"6","key":"5246_CR7","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s00277-015-2310-6","volume":"94","author":"A Messori","year":"2015","unstructured":"Messori A, Fadda V, Maratea D, Trippoli S (2015) First-line treatments for chronic lymphocytic leukaemia: interpreting efficacy data by network meta-analysis. Ann Hematol 94(6):1003\u20131009","journal-title":"Ann Hematol"},{"issue":"1","key":"5246_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40364-022-00357-5","volume":"10","author":"J Zhang","year":"2022","unstructured":"Zhang J, Lu X, Li J et al (2022) Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma. Biomark Res 10(1):17","journal-title":"Biomark Res"},{"issue":"17","key":"5246_CR9","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1158\/1078-0432.CCR-10-0570","volume":"16","author":"SJ Lemery","year":"2010","unstructured":"Lemery SJ, Zhang J, Rothmann MD, Yang J, Earp J, Zhao H et al (2010) U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res 16(17):4331\u20138","journal-title":"Clin Cancer Res"},{"issue":"10","key":"5246_CR10","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","volume":"28","author":"WG Wierda","year":"2010","unstructured":"Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A et al (2010) Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 28(10):1749\u20131755","journal-title":"J Clin Oncol"},{"issue":"9","key":"5246_CR11","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.3109\/10428194.2015.1122783","volume":"57","author":"A \u00d6sterborg","year":"2016","unstructured":"\u00d6sterborg A, Udvardy M, Zaritskey A, Andersson PO, Grosicki S, Mazur G et al (2016) Phase III, randomized study of ofatumumab versus physicians\u2019 choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leuk Lymphoma 57(9):2037\u20132046","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"5246_CR12","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/S1470-2045(15)00143-6","volume":"16","author":"MH van Oers","year":"2015","unstructured":"van Oers MH, Kuliczkowski K, Smolej L, Petrini M, Offner F, Grosicki S et al (2015) Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. Lancet Oncol 16(13):1370\u20131379","journal-title":"Lancet Oncol"},{"issue":"5","key":"5246_CR13","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1080\/10428194.2016.1233536","volume":"58","author":"T Robak","year":"2017","unstructured":"Robak T, Warzocha K, GovindBabu K, Kulyaba Y, Kuliczkowski K, Abdulkadyrov K et al (2017) Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. Leuk Lymphoma 58(5):1084\u20131093","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"5246_CR14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41408-019-0260-2","volume":"9","author":"M van Oers","year":"2019","unstructured":"van Oers M, Smolej L, Petrini M, Offner F, Grosicki S, Levin MD et al (2019) Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer J 9(12):98","journal-title":"Blood Cancer J"},{"issue":"2","key":"5246_CR15","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1001\/jamainternmed.2016.7761","volume":"177","author":"T Rupp","year":"2017","unstructured":"Rupp T, Zuckerman D (2017) Quality of life, overall survival, and costs of cancer drugs approved based on surrogate endpoints. JAMA Intern Med 177(2):276\u2013277","journal-title":"JAMA Intern Med"},{"issue":"12","key":"5246_CR16","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/jamainternmed.2015.5868","volume":"175","author":"C Kim","year":"2015","unstructured":"Kim C, Prasad V (2015) Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals. JAMA Intern Med 175(12):1992\u20131994","journal-title":"JAMA Intern Med"},{"issue":"3","key":"5246_CR17","doi-asserted-by":"publisher","first-page":"e114","DOI":"10.1016\/S2352-3026(17)30019-4","volume":"4","author":"JA Jones","year":"2017","unstructured":"Jones JA, Robak T, Brown JR, Awan FT, Badoux X, Coutre S et al (2017) Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol 4(3):e114\u2013e126","journal-title":"Lancet Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05246-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05246-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05246-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T10:20:09Z","timestamp":1683886809000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05246-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,3]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["5246"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05246-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,3]]},"assertion":[{"value":"15 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}